Ivor Elrifi, CEO of Tiziana Life Sciences, expressed enthusiasm about this milestone, stating, "We are excited to initiate this important clinical study with the support of the ALS Association grant.
NEW YORK, March 04, 2025) ("Tiziana" or the "Company"), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully hu ...
Tiziana Life Sciences (NASDAQ:TLSA) rises after the company said it is planning the submission of its Investigational New ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback